Approaches to Forming a Water-soluble Extracellular Domain From α3 Subunits of Nicotinic Acetylcholine Receptors by Frankovich, Victoria Lea
 
 
APPROACHES TO FORMING A WATER-SOLUBLE EXTRACELLULAR 
DOMAIN FROM α3 SUBUNITS OF NICOTINIC ACETYLCHOLINE 
RECEPTORS 
 
 
An Undergraduate Research Scholars Thesis 
by 
VICTORIA LEA FRANKOVICH 
 
 
Submitted to Honors and Undergraduate Research 
Texas A&M University 
in partial fulfillment of the requirements for the designation as an 
 
 
UNDERGRADUATE RESEARCH SCHOLAR 
 
 
Approved by 
Research Advisor:  Dr. Gregg Wells 
 
 
May 2014 
 
 
Major: Biochemistry 
  
 
 
TABLE OF CONTENTS 
Page 
ABSTRACT ................................................................................................................................  1 
ACKNOWLEDGMENTS ........................................................................................................... 3 
CHAPTER 
 I INTRODUCTION .............................................................................................. 4 
 II MATERIALS AND METHODS ........................................................................ 10 
Design of DNA Plasmids..................................................................................... 10 
Protein Expression in Xenopus Oocytes.............................................................. 10 
Immunoblotting.................................................................................................... 11 
Ligand Binding Assay.......................................................................................... 12 
 III RESULTS ............................................................................................................ 14 
Immunoblotting.................................................................................................... 14 
Ligand Binding Assay.......................................................................................... 15 
 IV CONCLUSION ................................................................................................... 17 
REFERENCES ............................................................................................................................ 20 
1 
 
ABSTRACT 
Approaches to Forming a Water-soluble Extracellular Domain from α3 Subunits of Nicotinic 
Acetylcholine Receptors. (May 2014) 
 
Victoria Lea Frankovich 
Department of Biochemistry and Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Gregg Wells 
Department of Molecular and Cellular Medicine 
Texas A&M Health Science Center 
 
Obtaining structural information on the extracellular domain (ECD) of α3 subunits of nicotinic 
acetylcholine receptors (nAChRs) by x-ray crystallography is desirable for the design of drugs 
intended to therapeutically target specific nAChRs and treat the various diseases and disorders 
caused by nAChR complications such as epilepsy, Alzheimer’s disease, Parkinson’s disease and 
other disorders of the nervous system. Separating the ECD from the rest of the structure is 
advantageous because the transmembrane domains make nAChRs difficult to crystallize. In 
order to explore the possibility of creating a water soluble ECD from the α3 subunits of nAChRs 
through the proteolysis of the ECD away from the transmembrane domains, the nAChR 
expression yield of mutant α3 nAChR subunits containing a flexible linker at the ECD/M1 
interface was measured. The flexible linker used was an 18 amino acid sequence consisting of 
the residues alanine-glycine-serine repeated six times (6xAGS) and was designed as a possible 
flexible environment in which to contain a protease site. The nAChR yield, as measured by yield 
of [
3
H]epibatidine binding sites, was much lower for the α3 nAChR subunits containing the 
flexible linker at the ECD/M1 interface than for the control subunits without the linker. 
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Therefore, the 6xAGS flexible linker is not the optimum environment in which to contain a 
protease site in α3 nAChR subunits.   
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CHAPTER I 
INTRODUCTION 
 
Nicotinic acetylcholine receptors (nAChRs) are essential for life. These receptors are integral 
membrane, ion channels that conduct cations and depolarize a cell when they switch from their 
closed to open state after a ligand binds the active site (13). They are activated by the 
neurotransmitter acetylcholine but are also sensitive to activation by nicotine (1).  nAChRs are 
located throughout the central and peripheral nervous system and consist of two major types: 
neuronal receptors and muscle-type receptors. Neuronal nAChRs are commonly found at five 
primary locations on the neuron: the cell soma, dendrites, preterminal axon regions, axon 
terminals, and the myelinated axons (1). The importance of these proteins comes from their 
ability to transmit signals from neuron to neuron though the release of the neurotransmitter 
acetylcholine. Nicotinic acetylcholine receptors have been shown to be linked to epilepsy, 
Alzheimer disease and Parkinson disease and have been implicated in schizophrenia, Tourette’s 
syndrome, anxiety and depression (8). 
 
Understanding the structure of nAChRs is essential for understanding their function and 
importance. The protein consists of a large, N-terminal extracellular domain which is responsible 
for ligand binding, four transmembrane domains, a cytoplasmic loop between the third and 
fourth transmembrane domains, and a Cys-loop made of two cysteine residues with a disulfide 
bond separated by 13 amino acid residues (13).  Each receptor is composed of five subunits. 
Currently 17 subunits have been identified and named α1-α10, β1-β4, δ, γ and ε (13). Each one 
of these subunits contains the four transmembrane domains and an N-terminal extracellular 
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domain. The pentameric assembly of N-terminal extracellular domains work together to form 
ligand binding sites at interfaces between subunits. The muscle-type nAChRs consist of an α1 
and 4 non-α (β,δ, or γ/ε) subunits, while the neuronal nAChRs can be homopentamers or 
heteropentamers that contain α1-10 or β1-4 in many different combinations (1). The subunits 
assemble to form a central pore through which cations can pass. This diversity of subunits allows 
organisms to produce a variety of receptors with specialized functions (1). 
 
The α3 subunit is mostly expressed in the autonomic nervous system (along with β4), whereas α4 
and β2 nAChR subunit expression dominates in the central nervous system (1). The α3β4 
nAChR subunits are also the predominant subunits expressed in the autonomic sensory ganglia 
(5).  However, α3 subunits can also be located in the brain, and are found mostly in the visual 
pathway, pineal gland, cerebellum and the retina (5).  The importance of the α3 nAChR subunit 
was tested by creating α3 genetic knockout mice. These mice experienced impaired growth, 
increased mortality, enlarged bladders, bladder infections, dribbling urination, urinary stones, 
extreme mydriasis and lack of pupil contraction in response to light (7). The large amount of 
bladder problems was probably due to the absence of α3-containing nAChRs in the 
parasympathetic intramural ganglia of the bladder and the eye problems were from the lack of 
α3-containing nAChRs in the nerve that controls the contraction and dilution of the pupil (14). 
These knockout mice showed the major effects of the α3 subunit within the autonomic nervous 
system.  
 
Obtaining structural information on nAChRs is vital to determine how they function as ion 
channels and signal transducers, learn their role in physiology, and understand the differences in 
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receptors within the Cys-loop receptor family (6). This knowledge will help design drugs that 
will therapeutically target particular types of receptors to cause specific effects and help treat 
some of the nAChR-related diseases and disorders that are suffered by many. In particular, 
obtaining structural information on the α3 nAChR subunit will show how the α3 subunit’s 
structure is different from the other subunits and will allow for drugs to be designed to 
therapeutically target specific types of receptors for effects within the autonomic nervous system.  
 
Some structural information has already been publicized regarding the structure of nAChRs. 
Electron diffraction of nAChRs was completed from muscle-type nAChRs in helical tubular 
crystals from Torpedo marmorata (an electric fish) at a 4 Å resolution, as well as x-ray 
crystallography of acetylcholine binding protein (AChBP) at about a 2 Å resolution (13). 
Structural models have also been developed for cys-loop bacterial receptors from Gloeobacter 
violaceus and Erwinia chrysanthemi (9). The problem with existing structural models of nAChR 
is that they have only partially reproduced ligand binding affinities and subunit assembly 
properties compared to full length receptors. A more tractable experimental model of full-length 
nAChR needs to be developed that possesses suitable structural properties of the full receptors. 
  
The ultimate goal of this project is to develop water soluble extracellular domain (ECD) nAChRs 
for x-ray crystallography. The extracellular domain is defined as the truncated subunits 
containing the N-terminal sequences including the ligand-binding region (6). This ECD segment 
should have the same ligand binding affinities and subunit assembly properties as the full length 
receptor. The transmembrane domains make nAChRs difficult to crystallize, so being able to 
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create just the ECD of nAChRs would allow the protein to crystallize more easily (6). The 
smaller molecular mass of the ECD could also make it a better option for NMR spectroscopy (6).  
 
Past research has shown that the ECD domain cannot be expressed by itself but needs to be 
expressed in junction with the M1 transmembrane domain (6). However, an epitope tag can be 
inserted at the M1/ECD junction in the α7 subunit without significantly altering ligand affinity 
(12). This suggests that a protease site could be inserted at the M1/ECD junction and be used to 
separate the ECD from the M1 domain after protein expression. The protein expression yields of 
just the ECD and M1 domains are significantly lower than yields of the full length nAChRs (10). 
This suggests that the full length nAChR should be expressed before using a protease enzyme to 
isolate the ECD. It has also been discovered that some amino acid residues at the interface of M1 
and the ECD need to be duplicated on both sides of the insert in order to successfully produce the 
nAChR with an inserted protease site (11). There has also been success in inserting a protease 
site at the ECD/M1 interface in α7 nAChR (12) and α4β2 nAChR (unpublished). Pursuing this 
same approach should also yield positive results with the α3 subunit nAChR. 
 
In order to determine how to maximize protein expression of the α3 nAChR subunit containing a 
protease site at the ECD/M1 junction, a nAChR mutant containing a non-native insert at the 
ECD/M1 junction was created. This non-native insert is a flexible linker domain consisting of 
the amino acids alanine-glycine-serine repeated six times (6xAGS). This linker could act as a 
flexible environment in which to insert the protease site in order to allow the protein more 
freedom to form its tertiary structure. This extra freedom and flexibility could make up for the 
decrease in protein expression that is seen when just the protease site is inserted into the protein. 
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I tested the ability of the α3 subunit to tolerate the 6xAGS linker at the ECD/M1 junction by 
evaluating the protein expression levels and measuring the yield of [
3
H]epibatidine binding sites 
as an indicator of the production of α3 nAChR.  
 
Epibatidine is a compound which binds with high affinity to α3 nAChR. Its ability to bind to the 
agonist binding site of α3 nAChR makes it a valuable tool for validating the structure of that site 
in structural models. When epibatidine is tagged with radioactive isotope tritium to form 
[
3
H]epibatidine, its binding can be detected with a liquid scintillation counter (2). In our ligand 
binding assay, our mutated protein product is incubated with [
3
H]epibatidine.  The amount of 
[
3
H]epibatidine that remains bound to the receptor is used to calculate the yield of 
[
3
H]epibatidine binding sites. The yield of [
3
H]epibatidine binding sites allows conclusions to be 
drawn about the successful formation of the receptor’s active site (2). Studies of the full length 
α3β4 nAChR and M1-containing α3β4 nAChR and their ability to bind [3H]epibatidine confirms 
that each receptor has two sites for binding [
3
H]epibatidine molecules (Fig. 1) (10). This two-site 
model will be taken into account when the yield of [
3
H]epibatidine binding sites is determined 
for the mutant α3 nAChR subunit containing the flexible linker. 
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Figure 1. [3H]epibatidine binding curves of full length and ECD α3β4 nAChR and M1 and ECD 
α3β4 nAChR. Data supports the presence of two sites in full length and ECD α3β4 nAChR. 
 
In this project, I created a mutant α3 nAChR subunit containing a flexible 6xAGS linker at the 
ECD/M1 junction and evaluated its expression levels in Xenopus laevis oocytes as well as 
evaluated its ability to bind [
3
H]epibatidine by calculating the yield of [
3
H]epibatidine binding 
sites. This information will allow us to determine if the flexible linker 6xAGS would be a good 
environment in which to contain a protease site in the α3 nAChR subunit and possibly other 
nAChR subunits. 
  
10 
 
CHAPTER II 
METHODS 
 
Design of DNA Plasmids 
The cDNA of the human α3 and β2 nAChR subunits were cloned into the pSP64A Poly(A) 
vector (Promega). Primers were designed that contained the genes encoding the new 6xAGS 
flexible linker and also the IRRL residues which occur naturally right before the M1 domain. 
The primers were designed to insert the linker between the M1 domain and the extracellular 
domain. They were then synthesized by Invitrogen. PCR was performed with Accuprime PFX 
DNA Polymerase (Invitrogen) to insert the 6xAGS sequence into the α3 subunit coding 
sequence.  The DNA was amplified by bacterial transformation in One Shot® OmniMAX™ 2 
T1 Chemically Competent E.coli (Invitrogen) and then purified and isolated with QIAfilter® 
Plasmid Midi Prep Kit from Qiagen. Sequencing was performed by Lone Star Labs to confirm 
the presence of the 6xAGS insert. The plasmid DNA containing the α3 Full and IRRL 6xAGS 
sequence was linearized using AseI restriction digest (New England Biolabs) and the correct 
linear DNA production was confirmed by gel electrophoresis. RNA production from the 
linearized DNA was performed using the Ambion mMessage mMachine® SP6 Kit. The RNA 
product was visualized and quantified by gel electrophoresis.  
 
Protein Expression in Xenopus Oocytes 
Oocytes from Xenopus laevis frogs were prepared using collagenase type 1 (Invitrogen) 
following standard procedures (4). Protein expression of the nAChR constructs was achieved by 
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injecting a 40 nl aliquot containing 20 ng of cRNA of a pair of nAChR subunits into the 
cytoplasm of each oocyte. This process was repeated for each pair of subunit constructs being 
studied. The oocytes were then incubated at 18°C for 3 days in 50% Leibovitz’s L-15 medium 
(Invitrogen) in 10 mM HEPES, pH 7.5, containing 10 units/ml penicillin, 10 µg/ml streptomycin, 
and 43 µg/ml gentamicin. After incubation, the oocytes were homogenized by hand in an ice-
cold buffer (Buffer A: in mM: 50 sodium phosphate, 50 NaCl, 5 EDTA, 5 EGTA, 5 
benzamidine, 15 iodoacetamide, pH 7.5) and then centrifuged for 30 minutes at 14,500 x g at 
4°C. The pellet was solubilized in a buffer (Buffer B: Buffer A with 2% w/v Triton X-100) with 
gentle agitation for 2 hours at 4°C. The mixture was then centrifuged again (30 min, 14,500 x g, 
4°C). The membrane fraction was the fraction that was extracted by the detergent, and it was 
used for all of the immunoblotting and ligand binding assays.  
 
Immunoblotting 
The samples were denatured by heating at 65°C for 5 minutes in 1% SDS and 15 mM 
dithiothreitol and separated by SDS-PAGE on a 12.5% acrylamide gel. The proteins were then 
transferred to an Immun-Blot™ polyvinylidene difluoride (PVDF) membrane (BioRad) using a 
GENIE
®
 electrophoretic transfer device (Idea Scientific) for 30 minutes. Before probing, the 
membrane was blocked over the weekend at 4°C with 5% powdered milk in PBS buffer and 
0.05% Tween
®
20. The primary antibody, anti-HA antibody (Roche), was diluted 1:5000 in 
blocking solution and incubated with the membrane overnight at 4°C. The membrane was 
washed a minimum of three times for one hour each wash with PBS and 0.05% Tween. Goat 
anti-mouse (Pierce) secondary antibody was diluted 1:5000 in blocking buffer and incubated 
with the membrane overnight at 4°C. The membrane was washed again for a minimum of three 
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times for one hour each wash with PBS and 0.05% Tween. The proteins on the membrane were 
then visualized on BioMax ML film (Eastman Kodak Co.) with SuperSignal West Dura 
Extended Duration Substrate (Pierce) according to the manufacturer’s instructions. 
 
Ligand Binding Assay 
Immulon 4 HBX plastic microwells (Thermo Labsystems) for solid phase binding assays were 
coated with the primary antibody, 35 mAb, diluted in 10 mM CAPSO to a concentration of 4 
µg/ml of CAPSO and incubated for 3 days.  Monoclonal antibody 35 was used as the primary 
antibody because it selectively binds α3 subunits of nAChR (3). Then the wells were washed 
with NaN3-PBS. After the wash, the wells were blocked with 3% bovine serum albumin, fraction 
V (EM Science), in PBS (in mM: 137 NaCl, 2.7 KCl, 1.4 KH2PO4 10 Na2HPO4), incubated for 2 
hours and washed with wash buffer. A volume of detergent extract containing the equivalent of 
0.5 to 2 injected oocytes was added to each mAb-coated microwell. The microwells were 
incubated overnight at 4°C and then washed with ice cold buffer B. In order to measure 
[
3
H]epibatidine binding, an aliquot, of an amount determined by the constructs, of (±)-
[
3
H]epibatidine  (PerkinElmer Life Sciences; specific activity: 55.8 Ci/mmol) in ice-cold buffer 
B was added to each microwell and incubated overnight at 4°C. After incubation, the microwells 
were washed with ice-cold buffer B and stripped with a solution of 5% SDS and 25 mM 
dithiothreitol in buffer B. A liquid scintillation counter was used to measure the amount of 
[
3
H]epibatidine bound for each sample. Each data point was the average of duplicate 
measurements. Yield was calculated as the amount of [
3
H]epibatidine binding sites per oocyte. 
The yield of [
3
H]epibatidine binding sites for each subunit combination was defined as the 
amount of bound [
3
H]epibatidine with a total [
3
H]epibatidine concentration of 1 nM. The 
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controls used were α3β2 or α3β4 nAChRs. Nonspecific binding was measured from uninjected 
oocytes. 
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CHAPTER III 
RESULTS 
 
Immunoblotting 
The mutated α3 nAChR subunit containing the 6xAGS flexible linker was injected into Xenopus 
laevis oocytes for protein expression in combination with a mutated β2 nAChR subunit 
containing the same flexible linker at the ECD/M1 junction and an HA epitope tag. A positive 
control, α4 full with a FLAG epitope tag paired with β2 full with a HA epitope tag, and a 
negative control, α3 full paired with β4 full, were also injected into the Xenopus laevis oocytes. 
The expressed proteins were purified and separated by SDS-PAGE on a 12.5% acrylamide gel. 
Protein expression of the mutant β2 nAChR subunit was confirmed by immunoblotting with anti-
HA antibody, which binds the HA epitope tag that was cloned into the N-terminus of the β2 
sequence. Visualization of the blot revealed that the β2 subunit protein containing the 6xAGS 
flexible linker segment was expressed at a level similar to the control β2 subunit which did not 
contain the flexible linker (Fig. 2). Uninjected oocytes were used as a control. 
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Figure 2. Immunoblotting. Probing with the anti-HA antibody revealed an adequate protein 
expression yield of nAChR β2 subunits containing the 6xAGS flexible linker. 
 
 
Ligand Binding Assay 
The ligand binding assay measured the yield of [
3
H]epibatidine binding sites on the expressed 
α3/β2 subunit pair containing the flexible linker. Yield of [3H]epibatidine binding sites was 
calculated by separating the receptors of interest from the oocyte lysate using microwells coated 
with the α3-specific mAb 35 antibody, and then incubating the bound, epitope-tagged subunits 
with [
3
H]epibatidine overnight. The amount of [
3
H]epibatidine bound to the receptors was 
measured using liquid scintillation counting and was measured in disintegrations per minute 
[DPM]. From these data the yield of [
3
H]epibatidine binding sites per oocyte was calculated 
using the specific activity of [
3
H]epibatidine adjusted for radioactive decay and a 1.0 nM 
concentration of [
3
H]epibatidine. This concentration was sufficient to saturate binding sites with 
native-like structure. α3/β4 full and α3/β2 full pairs without the flexible linker were used as 
controls along with uninjected oocytes. The assay was performed on the protein collected from 
two separate injections, because the oocytes can often vary in their protein expression levels. In 
the first injection, a very low yield of [
3
H]epibatidine binding sites was seen for the α3/β2 
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subunit pair containing the 6xAGS flexible linker compared to the controls without the linker. 
The second injection showed practically no yield of [
3
H]epibatidine binding sites (Fig. 3).  
 
 
 
Figure 3. Epibatidine binding assay. Very low yield of [
3
H]epibatidine binding sites was seen 
when the α3full 6xAGS was paired with the β2full 3xHA 6xAGS subunit as compared to the 
control subunits without the flexible linker. Uninjected oocytes were used as a control. 
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CHAPTER IV 
CONCLUSION 
 
We studied the effects of inserting a long flexible linker between the extracellular domain (ECD) 
and the first transmembrane domain on the ability of the α3 and β2 subunits of nicotinic 
acetylcholine receptors (nAChRs) to bind the ligand [
3
H]epibatidine and monoclonal anti-
nicotinic acetylcholine receptor antibody 35 in order to evaluate the ability of the linker to be 
used as a flexible environment in which to place a protease site. After expression of the mutated 
α3 subunits in combination with similarly mutated β2 nAChR subunits, the proteins were 
purified, separated on a SDS-PAGE gel, transferred to a membrane and probed with anti-HA 
antibody to detect the presence of the β2 subunits, which contained a HA epitope tag. As 
compared to the control, there was adequate expression of the β2 subunits. From the 
immunoblotting results it can be concluded that the 6xAGS flexible linker does not affect the 
ability of the protein, without consideration of tertiary structure, to be expressed and survive in 
the cell. 
 
 Epibatidine binds with a high affinity to neuronal nicotinic receptors and when it is tagged with 
radioactive isotope tritium its binding can be detected with a liquid scintillation counter (2). 
When the amount of [
3
H]epibatidine binding sites was measured for the mutated α3 nAChR 
subunits containing the 6xAGS flexible linker in combination with the β2 subunit containing the 
same linker it was found to be significantly lower than for the controls. The first oocyte injection 
showed some [
3
H]epibatidine binding, but it was almost 20 times less than the control. The 
second oocyte injection had even worse yield of [
3
H]epibatidine binding sites and was barely 
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detectable. This low yield of [
3
H]epibatidine binding sites for the mutated α3 and β2 nAChR 
subunits containing the 6xAGS flexible linker suggests that the protein is not forming its correct 
secondary and tertiary structure. Without the correct protein structure, the active site is not 
properly formed and the [
3
H]epibatidine is not able to bind. It can be concluded that the specific 
design of the flexible linker inserted between the ECD and the M1 domain negatively influences 
the protein’s ability to fold into its proper structure and is therefore a poor environment in which 
to place a protease site. 
 
The results of this study raised many questions on why this flexible linker destroyed the ability 
of the protein to form properly. One possibility is that the region between the ECD and the M1 
domain is crucial for forming the secondary and tertiary structure and adding the insert there 
disrupted some important interactions. Another possibility is that the length of this 6xAGS 
flexible linker was too long to allow the ECD and the active site to form properly.  
 
A new hypothesis was raised that we hope will answer some of these questions. We hypothesize 
that the length of an insertion at the extracellular domain/M1 interface affects yield of 
[
3
H]epibatidine binding sites of α3-containing nAChRs. To test this new hypothesis we have 
developed two new mutants containing inserts at the ECD/M1 interface in α3 subunit nAChRs. 
The first mutant contains a short sequence of only five amino acids. Testing this short sequence 
will reveal if the size of the insert influences protein expression and ligand binding. The second 
mutant contains a TEV protease site at the ECD/M1 junction. This TEV protease site is the 
minimal length necessary for site-specific proteolysis and could be used to liberate the 
extracellular domain after the protein has been expressed. The shorter length of these inserts at 
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the ECD/M1 junction will hopefully lead to increased yield of [
3
H]epibatidine binding sites for 
α3-containing nAChRs.  
 
Successful expression and binding of α3 nAChR subunits containing a protease site at the 
ECD/M1 junction would allow the same techniques to be applied to the other nAChR subunits. 
Use of the protease site to separate the ECD from the rest of the receptor would allow the study 
of how to best crystallize the ECD molecule to begin. Successful crystallization would allow the 
ECD and most importantly the ligand binding sites of the different subunits of nicotinic 
acetylcholine receptors to be studied. This valuable information could be used to enhance 
therapeutic drug design for these nicotinic acetylcholine receptors and possibly other related 
Cys-loop receptors and help treat the detrimental effects of neurological disorders. 
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